S
Susanne Schnittger
Researcher at University of Göttingen
Publications - 119
Citations - 6888
Susanne Schnittger is an academic researcher from University of Göttingen. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 44, co-authored 119 publications receiving 6109 citations. Previous affiliations of Susanne Schnittger include University of Lübeck.
Papers
More filters
Journal ArticleDOI
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T Haferlach,Yasunobu Nagata,Vera Grossmann,Yusuke Okuno,Ulrike Bacher,Genta Nagae,Susanne Schnittger,Masashi Sanada,Ayana Kon,Tamara Alpermann,Kenichi Yoshida,Andreas Roller,Niroshan Nadarajah,Yuichi Shiraishi,Yusuke Shiozawa,Kenichi Chiba,Hirokazu Tanaka,H P Koeffler,Hans-Ulrich Klein,Martin Dugas,Hiroyuki Aburatani,Alexander Kohlmann,Satoru Miyano,Claudia Haferlach,Wolfgang Kern,Seishi Ogawa +25 more
TL;DR: Large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Journal ArticleDOI
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV H status and immunophenotyping
TL;DR: Additional abnormalities are detectable providing new biological insights into different CLL subclasses revealing a much more heterogeneous pattern of cytogenetic abnormalities as assumed so far based on FISH data only, and prospective clinical trials should evaluate the prognostic impact of newly available CBA data.
Journal ArticleDOI
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML
Susanne Schnittger,U Kinkelin,Claudia Schoch,Achim Heinecke,Detlef Haase,T Haferlach,Th. Büchner,Bernhard Wörmann,Wolfgang Hiddemann,Frank Griesinger +9 more
TL;DR: MLL tandem duplications are less common than previously reported, are preferentially observed in AML with normal karyotypes, but can also be found in the presence of chromosome alterations; are not strongly associated with an FAB subtype; and identifies a subgroup of patients with an unfavorable prognosis.
Journal ArticleDOI
Landscape of TET2 mutations in acute myeloid leukemia
Sandra Weissmann,Tamara Alpermann,Vera Grossmann,A Kowarsch,Niroshan Nadarajah,C Eder,Frank Dicker,Annette Fasan,Claudia Haferlach,T Haferlach,Wolfgang Kern,Susanne Schnittger,Alexander Kohlmann +12 more
TL;DR: A role for TET2 as an important prognostic biomarker in AML is supported, that is, patients harboring mutated CEBPA and/or mutated NPM1 without FLT3-ITD as well as in patients of the European LeukemiaNet favorable-risk subgroup.
Journal ArticleDOI
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
Sabine Jeromin,Sandra Weissmann,Claudia Haferlach,Frank Dicker,K Bayer,Vera Grossmann,Tamara Alpermann,Andreas Roller,Alexander Kohlmann,T Haferlach,Wolfgang Kern,Susanne Schnittger +11 more
TL;DR: The data suggest that analysis of gene mutations refines the risk stratification of cytogenetic prognostic subgroups and confirms data of a recently proposed model integrating molecular and cytogenetics data.